Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJanuary 6, 2020ReblogShareTweetShareCAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 13, 2020 at 12:30 p.m. E.T. / 9:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:00 p.m. E.T. / 10:00 a.m. P.T.The presentation and Q&A session will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.About Sarepta TherapeuticsSarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For more information, please visit www.sarepta.com.Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.Investors: Ian Estepan, 617-274-4052 iestepan@sarepta.comMedia:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read Next5 Things You Should Know About Spinal Muscular AtrophyThe MightySarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss EstimatesZacksWhy a 'Rare Disease' Diagnosis Can Often Be a Death SentenceThe National InterestSarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue EstimatesZacksStaggering price tag for daughter's rare medical conditionCBS NewsBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo Finance